FLII and Ewing sarcoma: Although the t(11;22)(q24;q12) translocation was first described 33 years ago14 and numerous studies have validated that the tumorigenic phenotype of Ewing sarcoma is dependent on this master regulator, EWS/FLI-targeted therapies are only now beginning to be clinically evaluated.